Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players


#165776

N/A

GBI Research

$ 3500

In Stock


Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players

Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players’, which provides in-depth analysis of the key therapeutic indications of oncology, breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL), with forecasts until 2018. It also looks at treatment usage patterns and includes insights into the oncology R&D pipeline. 

The Indian oncology therapeutics market for breast cancer, lung cancer, colorectal cancer, prostate cancer and NHL was estimated to be worth $153.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 12.7% from 2004. It is expected to reach $238.8m in 2018 at a CAGR of 6.5% from 2011. The slower growth in the forecast period is mainly due to the reduction in the price of leading marketed products for breast cancer, colorectal cancer, lung cancer and NHL after all 348 drugs on the National List of Essential Medicines (NLEM) are brought under price control regulations. 

The limitations of the current market are unclear patent laws, restrictive pricing and reimbursement policies, ailing infrastructure, and insufficient government aid. Low patient affordability is also a major restraint, and one that reimbursement and insurance policies must address if the market is to develop in the future.

Scope

  • The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the breast cancer, colorectal cancer, prostate cancer, lung cancer and NHL markets.
  • The report includes:
  • Data and analysis for the oncology therapeutics market in India
  • Annualized market data for the oncology therapeutics market in India from 2004 to 2011, with forecasts to 2018
  • Key drivers and restraints that have had a significant impact on the market
  • The competitive landscape of the oncology therapeutics market in India
  • Key M&A activities and licensing agreements that have taken place in the Indian oncology therapeutics market

Reasons to Buy


The report will enhance your decision-making capability by allowing you to:

  • Align your product portfolio to the markets with high growth potential
  • Develop market-entry and market-expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the oncology market
  • Develop key strategic initiatives by understanding the key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Table of Contents

1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Oncology Therapeutics Market in India – Executive Summary
2.1 The Oncology Therapeutics Market in India is Expected to Witness Slower Growth Due to the Impending Price War
2.2 Fragmented Market in which the Top Five Companies Account for Less than 50% of the Market
2.3 Lung and Breast Cancer Dominate the Oncology Pipeline with a Share of 75%

3 Oncology Therapeutics Market in India – Introduction
3.1 GBI Research Report Guidance

4 Oncology Therapeutics Market in India – Market Overview
4.1 Population Dynamics
4.2 Cancer Registration Background in India
4.3 Most Common Cancers in India
4.4 Cancer Mortality Rate
4.5 Market Characterization and Forecasts
4.6 Annual Cost of Therapy
4.7 Treatment Usage Pattern
4.7.1 Diseased Population
4.7.2 Prescription Population
4.8 Drivers and Barriers
4.8.1 Drivers
4.8.2 Restraints

5 Oncology Therapeutics Market in India – Therapeutic Landscape
5.1 Breast Cancer
5.1.1 Disease Overview
5.1.2 Staging
5.1.3 Market Size
5.1.4 Annual Cost of Therapy
5.1.5 Treatment Usage Pattern
5.1.6 Key Marketed Products
5.1.7 Competitive Landscape
5.2 Colorectal Cancer
5.2.1 Disease Overview
5.2.2 Staging
5.2.3 Market Size
5.2.4 Annual Cost of Therapy
5.2.5 Treatment Usage Pattern
5.2.6 Key Marketed Products
5.2.7 Competitive Landscape
5.3 Prostate Cancer
5.3.1 Disease Overview
5.3.2 Staging
5.3.3 Market Size
5.3.4 Annual Cost of Therapy
5.3.5 Treatment Usage Pattern
5.3.6 Key Marketed Products
5.3.7 Competitive Landscape
5.4 Lung Cancer
5.4.1 Disease Overview
5.4.2 Staging
5.4.3 Market Size
5.4.4 Annual Cost of Therapy
5.4.5 Treatment Usage Pattern
5.4.6 Key Marketed Products
5.4.7 Competitive Landscape
5.5 Non-Hodgkin’s Lymphoma
5.5.1 Disease Overview
5.5.2 Staging
5.5.3 Market Size
5.5.4 Annual Cost of Therapy
5.5.5 Treatment Usage Pattern
5.5.6 Key Marketed Products
5.5.7 Competitive Landscape

6 Oncology Therapeutics Market in India – Pipeline Analysis
6.1 Introduction
6.2 Breast Cancer
6.2.1 Introduction
6.3 Colorectal Cancer
6.3.1 Introduction
6.4 Prostate Cancer
6.4.1 Introduction
6.5 Lung Cancer
6.5.1 Introduction
6.6 Non-Hodgkin’s Lymphoma
6.6.1 Introduction

7 Oncology Therapeutics Market in India – Competitive Landscape
7.1 Market Share Analysis
7.2 Competitive Profiling
7.2.2 Dr. Reddy’s Laboratories
7.2.3 Natco Pharma
7.2.4 AstraZeneca
7.2.5 Cipla

8 Oncology Therapeutics Market in India – Strategic Consolidations
8.1 Introduction
8.2 Merger & Acquisition Deals
8.2.1 M&A by Year
8.3 Licensing Agreements
8.3.1 Deals by Year
8.3.2 Major Licensing Deals
8.4 Co-Development Deals
8.4.1 Deals by Year
8.4.2 Major Co-Development Deals

9 Oncology Therapeutics Market in India – Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Bibliography
9.4 Research Methodology
9.4.1 Coverage
9.4.2 Secondary Research
9.4.3 Primary Research
9.4.4 Expert Panel Validation
9.5 Contact Us
9.6 Disclaimer

Table 1: Oncology Therapeutics Market, India, Incidence and Prevalence by Cancer Type, 2008
Table 2: Oncology Therapeutics Market, India, Estimated Cancer Deaths by Cancer Type, 2010
Table 3: Oncology Therapeutics Market, India, Revenue ($m), 2004–2011
Table 4: Oncology Therapeutics Market, India, Revenue Forecast ($m), 2011–2018
Table 5: Oncology Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011
Table 6: Oncology Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018
Table 7: Oncology Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2011
Table 8: Oncology Therapeutics Market, India, Treatment Usage Pattern (‘000), 2011–2018
Table 9: Breast Cancer Therapeutics Market, India, Staging Description, 2012
Table 10: Breast Cancer Therapeutics Market, India, Staging Grouping, 2012
Table 11: Breast Cancer Therapeutics Market, India, Revenue ($m), 2004–2011
Table 12: Breast Cancer Therapeutics Market, India, Revenue Forecast ($m), 2011–2018
Table 13: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011
Table 14: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018
Table 15: Breast Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2011
Table 16: Breast Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2011–2018
Table 17: Breast Cancer Therapeutics Market, India, Key Marketed Products, 2011
Table 18: Colorectal Cancer Therapeutics Market, India, Staging Description, 2012
Table 19: Colorectal Cancer Therapeutics Market, India, Staging Grouping, 2012
Table 20: Colorectal Cancer Therapeutics Market, India, Revenue ($m), 2004–2011
Table 21: Colorectal Cancer Therapeutics Market, India, Revenue Forecast ($m), 2011–2018
Table 22: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011
Table 23: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018
Table 24: Colorectal Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2011
Table 25: Colorectal Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2001–2018
Table 26: Colorectal Cancer Therapeutics Market, India, Key Marketed Products, 2011
Table 27: Prostate Cancer Therapeutics Market, India, Staging Description, 2012
Table 28: Prostate Cancer Therapeutics Market, India, Staging Grouping, 2012
Table 29: Prostate Cancer Therapeutics Market, India, Revenue ($m), 2004–2011
Table 30: Prostate Cancer Therapeutics Market, India, Revenue Forecast ($m), 2011–2018
Table 31: Prostate Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011
Table 32: Prostate Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018
Table 33: Prostate Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2011
Table 34: Prostate Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2011–2018
Table 35: Prostate Cancer Therapeutics Market, India, Key Marketed Products, 2011
Table 36: Lung Cancer Therapeutics Market, India, Staging Description, 2012
Table 37: Lung Cancer Therapeutics Market, India, Staging Grouping, 2012
Table 38: Lung Cancer Therapeutics Market, India, Revenue ($m), 2004–2011
Table 39: Lung Cancer Therapeutics Market, India, Revenue Forecast ($m), 2011–2018
Table 40: Lung Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011
Table 41: Lung Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018
Table 42: Lung Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2011
Table 43: Lung Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2011–2018
Table 44: Lung Cancer Therapeutics Market, India, Key Marketed Products, 2011
Table 45: Non-Hodgkin’s Lymphoma Therapeutics Market, India, Staging Description, 2012
Table 46: Non-Hodgkin’s Lymphoma Therapeutics Market in India, Revenue ($m), 2004–2011
Table 47: Non-Hodgkin’s Lymphoma Therapeutics Market, India, Revenue Forecast ($m), 2011–2018
Table 48: Non-Hodgkin’s Lymphoma Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011
Table 49: Non-Hodgkin’s Lymphoma Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018
Table 50: Non-Hodgkin’s Lymphoma Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2011
Table 51: Non-Hodgkin’s Lymphoma Therapeutics Market, India, Treatment Usage Pattern (‘000), 2011–2018
Table 52: Non-Hodgkin’s Lymphoma Therapeutics Market, India, Key Marketed Products, 2011
Table 53: Oncology Therapeutics Market, India, Breast Cancer Pipeline by Phase, 2012
Table 54: Oncology Therapeutics Market, India, Breast Cancer Pipeline, Phase I, 2012
Table 55: Oncology Therapeutics Market, India, Breast Cancer Pipeline, Phase I/II, 2012
Table 56: Oncology Therapeutics Market, India, Breast Cancer Pipeline, Phase II, 2012
Table 57: Oncology Therapeutics Market, India, Breast Cancer Pipeline, Phase III, 2012
Table 58: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline by Phase, 2012
Table 59: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline, Phase I/II, 2012
Table 60: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline, Phase II, 2012
Table 61: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline, Phase II/III, 2012
Table 62: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline, Phase III, 2012
Table 63: Oncology Therapeutics Market, India, Prostate Cancer Pipeline by Phase, 2012
Table 64: Oncology Therapeutics Market, India, Prostate Cancer Pipeline, Phase II, 2012
Table 65: Oncology Therapeutics Market, India, Prostate Cancer Pipeline, Phase III, 2012
Table 66: Oncology Therapeutics Market, India, Lung Cancer Pipeline by Phase, 2012
Table 67: Oncology Therapeutics Market, India, Lung Cancer Pipeline, Phase I/II, 2012
Table 68: Oncology Therapeutics Market, India, Lung Cancer Pipeline, Phase II, 2012
Table 69: Oncology Therapeutics Market, India, Lung Cancer Pipeline, Phase III, 2012
Table 70: Oncology Therapeutics Market, India, Non-Hodgkin’s Lymphoma Pipeline by Phase, 2012
Table 71: Oncology Therapeutics Market, India, Non-Hodgkin’s Lymphoma Pipeline, Phase II/III, 2012
Table 72: Oncology Therapeutics Market, India, Non-Hodgkin’s Lymphoma Pipeline, Phase III, 2012

Figure 1: Oncology Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 2: Oncology Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011
Figure 3: Oncology Therapeutics Market, India, R&D Pipeline by Indication (%), 2012
Figure 4: Oncology Therapeutics Market, India, Population Growth Forecast (million), 2001–2025
Figure 5: Oncology Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 6: Oncology Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018
Figure 7: Oncology Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2018
Figure 8: Oncology Therapeutics Market, India, Key Drivers and Barriers, 2012
Figure 9: Breast Cancer Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 10: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018
Figure 11: Breast Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2018
Figure 12: Breast Cancer Therapeutics Market, India, Top Manufacturers, Market Share, 2011
Figure 13: Colorectal Cancer Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 14: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018
Figure 15: Colorectal Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2018
Figure 16: Colorectal Cancer Therapeutics Market, India, Top Manufacturers, Market Share, 2011
Figure 17: Prostate Cancer Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 18: Prostate Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018
Figure 19: Prostate Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2018
Figure 20: Prostate Cancer Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011
Figure 21: Lung Cancer Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 22: Lung Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018
Figure 23: Lung Cancer Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2018
Figure 24: Lung Cancer Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011
Figure 25: Non-Hodgkin’s Lymphoma Therapeutics Market, India, Revenue Forecast ($m), 2004–2018
Figure 26: Non-Hodgkin’s Lymphoma Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018
Figure 27: Non-Hodgkin’s Lymphoma Therapeutics Market, India, Treatment Usage Pattern (‘000), 2004–2018
Figure 28: Non-Hodgkin’s Lymphoma Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011
Figure 29: Oncology Therapeutics Market, India, R&D Pipeline by Indication (%), 2012
Figure 30: Oncology Therapeutics Market, India, Breast Cancer Pipeline by Phase (%), 2012
Figure 31: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline by Phase (%), 2012
Figure 32: Oncology Therapeutics Market, India, Prostate Cancer Pipeline by Phase (%), 2012
Figure 33: Oncology Therapeutics Market, India, Lung Cancer Pipeline by Phase (%), 2012
Figure 34: Oncology Therapeutics Market, India, Non-Hodgkin’s Lymphoma Pipeline by Phase (%), 2012
Figure 35: Oncology Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011
Figure 36: Oncology Therapeutics Market, India, Hoffmann-La Roche, SWOT Analysis, 2011
Figure 37: Oncology Therapeutics Market, India, Dr. Reddy’s Laboratories, SWOT Analysis, 2011
Figure 38: Oncology Therapeutics Market, India, Natco Pharma, SWOT Analysis, 2011
Figure 39: Oncology Therapeutics Market, India, AstraZeneca, SWOT Analysis, 2011
Figure 40: Oncology Therapeutics Market, India, Cipla, SWOT Analysis, 2011
Figure 41: Oncology Therapeutics Market, India, Strategic Consolidation, Deals by Type, 2008–2012
Figure 42: Oncology Therapeutics Market, India, M&A by Year, 2008–2012
Figure 43: Oncology Therapeutics Market, India, Licensing Agreements by Year, 2008–2012
Figure 44: Oncology Therapeutics Market, India, Co-Development Deals by Year, 2008–2012